We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Terns

News List

Terns Announces Positive Interim Results from Ongoing Trial of TERN-201 americanpharmaceuticalreview
August 14, 2019
Terns Pharmaceuticals announced the interim results of an ongoing Phase 1 clinical trial of TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, being developed for the treatment of NASH.
Terns to commercialise GENFIT’s elafibranor to treat NASH and PBC pharmaceutical-technology
June 27, 2019
Terns Pharmaceuticals has signed an agreement to acquire the exclusive rights to develop, register and market GENFIT’s elafibranor.
Terns Acquires Rights to Develop, Commercialize Three NASH Assets from Lilly americanpharmaceuticalreview
April 09, 2018
Terns Pharmaceuticals has signed a global, exclusive license agreement with Eli Lilly and Company to develop, manufacture and commercialize three small molecule therapeutic candidates